Table 2.

Univariate and multivariate Cox proportional hazards analysis of FOXP4-AS1 expression and OS for patients with OVs in the validation cohort.

	Univariate analysis		Multivariate analysis
Characteristic	Hazard ratio (95% CI)	P	Hazard ratio (95% CI)	P
FIGO stage (Stage I–II vs. Stage III–IV)	2.085 (0.925–4.699)	.076	2.817 (0.691–11.485)	.149
Histologic grade (G1–2 vs G3–4)	1.194 (0.797–1.789)	.389
Primary therapy outcome (SD-PD vs PR-CR)	0.306 (0.207–0.451)	<.001	0.313 (0.206–0.474)	<.001
Age (<60 vs >=60)	1.329 (1.025–1.722)	.032	1.204 (0.881–1.645)	.243
Tumor residual (NRD vs RD)	2.302 (1.479–3.583)	<.001	2.062 (1.243–3.419)	.005
Lymphatic invasion (NO vs YES)	1.422 (0.839–2.411)	.191
Venous invasion (NO vs YES)	0.905 (0.487–1.683)	.753
Anatomic subdivision (unilateral vs bilateral)	1.041 (0.768–1.41)	.798
FOXP4-AS1 (low vs high)	0.685 (0.528–0.889)	.004	0.638 (0.467–0.871)	.005

CI = confidence interval, CR = complete remission, NRD = no residual disease, OS = overall survival, OVs = ovarian serous cystadenocarcinoma, PD = progressive disease, PR = partial remission, RD = residual disease, SD = stable disease.